Benjamin Garmezy, MD

Articles by Benjamin Garmezy, MD

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,David Morris, MD, MS,Tanya B. Dorff, MD,Mark T. Fleming, MD

March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,Petros Grivas, MD, PhD,David Morris, MD, MS

March 4th 2025

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Benjamin Garmezy, MD

Articles by Benjamin Garmezy, MD

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Trending on CancerNetwork

Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML

Survival Benefit Seen With Cilta-Cel in Earlier Lines of Myeloma Treatment

Early Efficacy Highlighted With Odronextamab/CHOP in Untreated DLBCL

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma